(secondQuint)Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

 Screening will be performed within 21 days of dosing on Day 1 at visit 2.

 Eligible participants will be admitted to the trial center the day preceding the first dosing (day -1).

 Participants will receive Aclidinium Bromide/Formoterol Fumarate 400/12 1/2g twice-daily (morning and evening) on Days 1 to 4.

 On Day 5 patients will receive the morning dose only.

 PK and safety assessments will be conducted at specific timepoints on Day 1 to Day 7.

 Participants will be discharged 48 h after the last administration of investigational product and completion of the 48-h PK sample collection and safety assessments on Day 7.

 A follow-up visit will be performed within 5 days of the last PK sample collection on Day 7.

.

 Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease@highlight

A Phase IIa, open-label, repeat-dose trial to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide/Formoterol Fumarate 400/12 1/2g in 20 Chinese male and female patients with stable moderate to severe COPD.

